NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Forecast, Price & News $1.10 +0.01 (+0.92%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.07▼$1.1750-Day Range$0.51▼$1.4352-Week Range$0.24▼$1.63Volume1.77 million shsAverage Volume2.38 million shsMarket Capitalization$204.52 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside81.8% Upside$2.00 Price TargetShort InterestHealthy2.19% of Shares Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment-0.13Based on 12 Articles This WeekInsider TradingSelling Shares$261,587 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.28) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector287th out of 983 stocksPharmaceutical Preparations Industry126th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Akebia Therapeutics has a forecasted upside of 81.8% from its current price of $1.10.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.19% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 9.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 57.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.35. Previous Next 1.6 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search Interest21 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $261,587.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 28.13% of the stock of Akebia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Akebia Therapeutics (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.Read More Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Stock News HeadlinesJune 2, 2023 | msn.comAkebia settles last patent lawsuit related to kidney disease therapyJune 2, 2023 | finance.yahoo.comAre Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?June 3, 2023 | Stansberry Research (Ad)Why 2023 Could Kick Off a "Cash Frenzy" in StocksBut the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.June 2, 2023 | finance.yahoo.comAll You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to BuyMay 31, 2023 | msn.comPiper Sandler Upgrades Akebia Therapeutics (AKBA)May 31, 2023 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded to Overweight by Piper SandlerMay 30, 2023 | seekingalpha.comAkebia says FDA denied appeal for kidney disease candidateMay 30, 2023 | msn.comAkebia Therapeutics Soars on Way Forward for Vadadustat in the U.S.June 3, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.May 30, 2023 | markets.businessinsider.comAkebia: FDA Denies Formal Dispute Resolution, But Provides Company Path Forward For VadadustatMay 30, 2023 | finance.yahoo.comFDA Provides Akebia Therapeutics a Path Forward for VadadustatMay 29, 2023 | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Drop in Short InterestMay 28, 2023 | americanbankingnews.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Sells $77,086.92 in StockMay 27, 2023 | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) COO Michel Dahan Sells 95,478 SharesMay 27, 2023 | americanbankingnews.comAkebia Therapeutics Sees Unusually Large Options Volume (NASDAQ:AKBA)May 26, 2023 | msn.comHC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Neutral RecommendationMay 26, 2023 | markets.businessinsider.comAnalyst Ratings for Akebia TherapeuticsMay 26, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Akebia Therapeutics (AKBA)May 26, 2023 | msn.comThe Latest Analyst Ratings for Akebia TherapeuticsMay 25, 2023 | finance.yahoo.comAkebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and AustraliaMay 23, 2023 | finance.yahoo.comWhy Shares of Akebia Therapeutics Were Up TuesdayMay 23, 2023 | markets.businessinsider.comThese 14 Biotech Stocks Hit New Highs, Did You Get In Early?May 23, 2023 | seekingalpha.comAkebia Therapeutics regains Nasdaq complianceMay 22, 2023 | finance.yahoo.comAkebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 22, 2023 | seekingalpha.comAkebia Therapeutics wins UK approval of vadadustat for CKD anemiaMay 22, 2023 | markets.businessinsider.comAkebia Therapeutics Announces UK MHRA Marketing Authorization For VafseoMay 22, 2023 | msn.comAkebia Therapeutics's Return On Capital Employed OverviewSee More Headlines AKBA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBA Company Calendar Last Earnings3/09/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees426Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+81.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,560,000.00 Net Margins-20.79% Pretax Margin-20.79% Return on Equity-235.17% Return on Assets-10.55% Debt Debt-to-Equity Ratio3.65 Current Ratio1.46 Quick Ratio1.21 Sales & Book Value Annual Sales$271.03 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-13.75Miscellaneous Outstanding Shares185,928,000Free Float179,086,000Market Cap$204.52 million OptionableOptionable Beta0.73 Key ExecutivesJohn P. ButlerPresident, Chief Executive Officer & DirectorMichel DahanChief Operating Officer & Senior Vice PresidentDavid A. SpellmanTreasurer, Chief Financial & Accounting OfficerSteven K. BurkeChief Medical Officer & SVP-Research & DevelopmentMichael RabinowitzVice President-ResearchKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCMerrimack PharmaceuticalsNASDAQ:MACKCue BiopharmaNASDAQ:CUEAC ImmuneNASDAQ:ACIUImmutepNASDAQ:IMMPView All CompetitorsInsiders & InstitutionsMichel DahanSold 95,478 sharesTotal: $116,483.16 ($1.22/share)Nicole R HadasSold 63,186 sharesTotal: $77,086.92 ($1.22/share)JPMorgan Chase & Co.Bought 77,503 shares on 5/18/2023Ownership: 0.044%State Street CorpBought 120,900 shares on 5/16/2023Ownership: 0.373%Steven Keith BurkeSold 63,567 sharesTotal: $68,016.69 ($1.07/share)View All Insider TransactionsView All Institutional Transactions AKBA Stock - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AKBA shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 1 year target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2023? Akebia Therapeutics' stock was trading at $0.5770 at the beginning of 2023. Since then, AKBA stock has increased by 90.6% and is now trading at $1.10. View the best growth stocks for 2023 here. Are investors shorting Akebia Therapeutics? Akebia Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 4,070,000 shares, a decrease of 9.6% from the April 30th total of 4,500,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is currently 2.4 days. View Akebia Therapeutics' Short Interest. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Thursday, March, 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The biopharmaceutical company earned $55.18 million during the quarter, compared to analysts' expectations of $48.35 million. Akebia Therapeutics had a negative net margin of 20.79% and a negative trailing twelve-month return on equity of 235.17%. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (8.72%), BlackRock Inc. (1.45%), Renaissance Technologies LLC (1.26%), State Street Corp (0.37%), Connor Clark & Lunn Investment Management Ltd. (0.16%) and Victory Capital Management Inc. (0.14%). Insiders that own company stock include David A Spellman, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $1.10. How much money does Akebia Therapeutics make? Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $204.52 million and generates $271.03 million in revenue each year. The biopharmaceutical company earns $-92,560,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. How many employees does Akebia Therapeutics have? The company employs 426 workers across the globe. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099. This page (NASDAQ:AKBA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.